Demetrius Albanes, M.D.
Biography
Dr. Albanes received a B.S. in biology from the State University of New York at Stony Brook and his M.D. degree from the Medical College of Wisconsin. Dr. Albanes entered the Epidemic Intelligence Service of the Centers for Disease Control (CDC) through which he began working in the cancer prevention program of the NCI in 1982. Thereafter, Dr. Albanes completed a Preventive Medicine residency with the CDC and continued his research in the Cancer Prevention Studies Branch of NCI from 1984 to 1990, when he received scientific tenure. He joined the Division of Cancer Epidemiology and Genetics in 2000 as a senior investigator in the Nutritional Epidemiology Branch, and served as Chief of the DCEG Office of Education until 2008. Dr. Albanes is principal investigator of the landmark Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study and serves as chair of the NIH Committee on Scientific Conduct and Ethics.
Research Interests
Dr. Albanes conducts a molecular epidemiologic program of biochemical, genetic, and mechanistic investigations focused on prostate and other cancers in relation to micronutrients (particularly vitamins D, E, and A), vitamin supplementation, and metabolite profiles. His recent prospective metabolomic studies have discovered novel serologic profiles for prostate cancer, glioma, and vitamin supplementation/serology. Dr. Albanes has also highlighted the importance of hyperinsulinemia, a hyperthyroid state, higher vitamin D and A status, and lower vitamin E status in elevated prostate cancer risk. This high-incidence malignancy is of essentially unknown etiology other than being more frequent in men with a first-degree family history of the disease, in men of African descent, and associated with over 400 common genetic variants.
Micronutrients and Cancer
Our ATBC Study found 18% higher lung cancer incidence in men supplemented with 20 mg beta-carotene daily for 5-8 years, and 32% lower prostate cancer incidence in those receiving 50 IU vitamin E. Although the latter finding was not confirmed in a subsequent 400 IU high-dose trial which led to 17% higher prostate cancer incidence, it indicated that vitamin supplementation at supra-physiological dosages could have deleterious health outcomes. By contrast, that a low, physiological dose of vitamin E may prevent prostate cancer remains an active hypothesis that is supported by our blood-based investigations.
Our investigations of the role of vitamin D in cancer has included prospective nested case-control studies measuring the accepted biomarker of vitamin D status, 25-hydroxy-vitamin D (25(OH)D), and its major carrier protein, vitamin D binding protein (DBP); analyses of vitamin D genes; and cell culture experiments testing vitamin D-androgen biological mechanisms. Based in part on our research, there is consensus in the field that, 1) men with higher vitamin D status are at increased prostate cancer risk, 2) a beneficial, preventive association exists for colorectal cancer, and, 3) null associations exist for most other organ sites, including breast cancer. Many of these biochemical associations are supported by our analyses of vitamin D genetic variants/polygenic scores based on our genome-wide association study (GWAS) findings for the 25(OH)D phenotype. We have also found a paradoxical beneficial association for higher vitamin D
Metabolomic Profiling of Cancer Risk
Metabolomic profiling of blood represents a relatively new agnostic, "broad-spectrum" approach for examining potential metabolic biomarkers of cancer risk. We initiated a program to prospectively investigate serum metabolites associated with cancer risk and survival, and found associations for several amino acid, peptide, fatty acide, and lipid compounds with prostate cancer. We showed a very different metabolite profile for risk of glioma that included sphihngomyelins. The observed patterns provide new potential leads regarding the molecular basis relevant to etiologic or sub-clinical biomarkers for prostate cancer and glioma that we are pursuing in the Consortium of Metabolomics Studies (COMETS).
Metabolomic and Genetic Studies of Vitamin Status
Within the ATBC Study, we have conducted a serum metabolomic profile of response to beta-carotene supplementation that revealed dysregulation of xenobiotic metabolism, and observed a number of lipid metabolites associated with serum vitamin D, including for example, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF). Our ATBC Study also participated in large international cancer genetic consortia that have identified hundreds of low-penetrance variants associated with risk, and we applied these GWAS data to serum vitamin status (including supplementation); e.g., identifying four genes associated with vitamin D status—GC, CYP2R1, DHCR7, and CYP24B1—which collectively explained ~5% of vitamin D variance. By applying this vitamin D genetic score in a multi-cohort prostate cancer risk analyses we confirmed the same causal direction for higher vitamin D which provided an unbiased confirmation of our biochemical findings.
Information for Journalists
To request an interview with a DCEG investigator, please complete this form NIH Request For Comment | HHS.gov.